News & Updates
Filter by Specialty:
Intramuscular injection preferable to IV infusion of ibalizumab for PWH
Ibalizumab delivered via intramuscular (IM) injection is not only safe and well-tolerated but also succeeds in viral suppression among heavily treatment experienced (HTE) people living with HIV (PWH), making IM the preferred method of administration among participants of the TMB-302 study.
Intramuscular injection preferable to IV infusion of ibalizumab for PWH
22 Mar 2024
ESK-001 makes good STRIDEs for plaque psoriasis
In the phase II dose-ranging STRIDE trial presented at AAD 2024, ESK-001, a highly-selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, demonstrated favourable efficacy and safety signals for the treatment of adults with moderate-to-severe plaque psoriasis.
ESK-001 makes good STRIDEs for plaque psoriasis
22 Mar 2024
Low-dose semaglutide spurs MASLD regression in people with HIV
Treatment with low-dose semaglutide helps reduce the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV, according to data from the single-arm phase IIb ACTG A5371 trial.
Low-dose semaglutide spurs MASLD regression in people with HIV
21 Mar 2024
Can’t stress enough: Healthy living prevents T2D
Adherence to a healthy lifestyle, particularly a well-balanced diet, protects against the development of type 2 diabetes (T2D), with differences across ethnicities, suggests a US study.
